MA50474A - Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1 - Google Patents
Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1Info
- Publication number
- MA50474A MA50474A MA050474A MA50474A MA50474A MA 50474 A MA50474 A MA 50474A MA 050474 A MA050474 A MA 050474A MA 50474 A MA50474 A MA 50474A MA 50474 A MA50474 A MA 50474A
- Authority
- MA
- Morocco
- Prior art keywords
- glp
- agonists
- receptor
- long
- acting glucagon
- Prior art date
Links
- 102000051325 Glucagon Human genes 0.000 title 1
- 108010063919 Glucagon Receptors Proteins 0.000 title 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title 1
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
- 229960004666 glucagon Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762562674P | 2017-09-25 | 2017-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50474A true MA50474A (fr) | 2020-09-02 |
Family
ID=65810991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050474A MA50474A (fr) | 2017-09-25 | 2018-09-21 | Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11566057B2 (fr) |
| EP (1) | EP3700550A4 (fr) |
| JP (3) | JP2020535138A (fr) |
| KR (1) | KR102505628B1 (fr) |
| CN (1) | CN111132690A (fr) |
| AU (1) | AU2018338184B2 (fr) |
| BR (1) | BR112020005841A8 (fr) |
| CA (2) | CA3076496A1 (fr) |
| MA (1) | MA50474A (fr) |
| MX (1) | MX2020003217A (fr) |
| WO (1) | WO2019060660A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022004872A (es) * | 2019-10-22 | 2022-05-13 | Nuritas Ltd | Tratamiento de enfermedad de higado graso no alcoholico. |
| EP3842060A1 (fr) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Co-agonistes lactames agrafés des récepteurs du glucagon et du glp-1 |
| EP3842449A1 (fr) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Co-agonistes d'oléfine agrafés du glucagon et récepteurs glp-1 |
| EP3842061A1 (fr) | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Co-agonistes triazoles agrafés des récepteurs du glucagon et du glp-1 |
| US12122817B2 (en) * | 2020-09-22 | 2024-10-22 | Serpentide Inc. | Long-lasting GLP1 analogue drug for type-2 diabetes |
| WO2022159395A1 (fr) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions et procédés pour le traitement de troubles métaboliques et hépatiques |
| WO2023006923A1 (fr) * | 2021-07-30 | 2023-02-02 | Boehringer Ingelheim International Gmbh | Schéma posologique pour agonistes du récepteur glp1/glucagon à action prolongée |
| MX2024003236A (es) | 2021-09-15 | 2024-06-19 | Viking Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos. |
| CN117586373A (zh) * | 2022-08-10 | 2024-02-23 | 成都奥达生物科技有限公司 | 一种长效双激动剂化合物 |
| WO2024165571A2 (fr) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibiteurs d'expression et/ou de fonction |
| EP4724471A1 (fr) * | 2023-06-09 | 2026-04-15 | Sun Pharmaceutical Industries Limited | Agonistes du récepteur double glp-1/gip, double glp-1/gcg et triple glp-1/gip/gcg |
| WO2025125576A2 (fr) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibiteurs d'expression et/ou de fonction |
| EP4686757A1 (fr) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibiteurs d expression et/ou de fonction |
| WO2025133348A1 (fr) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibiteurs d'expression et/ou de fonction |
| WO2025196502A1 (fr) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Inhibiteurs de choline kinase utilisés en tant que traitement thérapeutique contre l'obésité |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6852690B1 (en) | 1995-08-22 | 2005-02-08 | Amylin Pharmaceuticals, Inc. | Method and composition for enhanced parenteral nutrition |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| GB0308801D0 (en) * | 2003-04-16 | 2003-05-21 | Celltech R&D Ltd | Chemical compounds |
| RU2485135C2 (ru) | 2005-06-13 | 2013-06-20 | Импиэриэл Инноувейшнс Лимитид | Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты) |
| AU2008216265B2 (en) | 2007-02-15 | 2014-04-03 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| EP2300037B1 (fr) | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Co-agonistes du récepteur glucagon/glp-1 |
| WO2010096052A1 (fr) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Analogues d'oxyntomoduline |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| BR112013032717A2 (pt) | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
| RS56173B1 (sr) | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
| CR20170164A (es) * | 2014-10-24 | 2017-08-29 | Merck Sharp & Dohme | Coagonistas de los receptores de glucagón y de glp-1 |
| WO2017074798A2 (fr) * | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Co-agonistes à action longue durée des récepteurs du glucagon et du glp-1 |
| EP3430033A4 (fr) * | 2016-03-18 | 2019-11-20 | Merck Sharp & Dohme Corp. | Conjugués d'insuline-incrétine |
-
2018
- 2018-09-21 WO PCT/US2018/052124 patent/WO2019060660A1/fr not_active Ceased
- 2018-09-21 AU AU2018338184A patent/AU2018338184B2/en not_active Ceased
- 2018-09-21 CA CA3076496A patent/CA3076496A1/fr active Pending
- 2018-09-21 MA MA050474A patent/MA50474A/fr unknown
- 2018-09-21 BR BR112020005841A patent/BR112020005841A8/pt not_active Application Discontinuation
- 2018-09-21 US US16/643,881 patent/US11566057B2/en active Active
- 2018-09-21 MX MX2020003217A patent/MX2020003217A/es unknown
- 2018-09-21 EP EP18858623.4A patent/EP3700550A4/fr active Pending
- 2018-09-21 CA CA3220650A patent/CA3220650A1/fr active Pending
- 2018-09-21 KR KR1020207011622A patent/KR102505628B1/ko active Active
- 2018-09-21 CN CN201880062111.1A patent/CN111132690A/zh active Pending
- 2018-09-21 JP JP2020516798A patent/JP2020535138A/ja active Pending
-
2023
- 2023-03-02 JP JP2023032146A patent/JP2023071869A/ja active Pending
- 2023-09-06 JP JP2023144460A patent/JP2023171744A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020114220A (ru) | 2021-10-27 |
| BR112020005841A2 (pt) | 2020-11-17 |
| US20200270325A1 (en) | 2020-08-27 |
| AU2018338184B2 (en) | 2023-04-13 |
| AU2018338184A1 (en) | 2020-03-12 |
| EP3700550A1 (fr) | 2020-09-02 |
| WO2019060660A1 (fr) | 2019-03-28 |
| BR112020005841A8 (pt) | 2023-04-11 |
| JP2023171744A (ja) | 2023-12-05 |
| JP2023071869A (ja) | 2023-05-23 |
| US11566057B2 (en) | 2023-01-31 |
| KR20200057059A (ko) | 2020-05-25 |
| KR102505628B1 (ko) | 2023-03-02 |
| CA3220650A1 (fr) | 2019-03-28 |
| RU2020114220A3 (fr) | 2021-12-28 |
| CN111132690A (zh) | 2020-05-08 |
| JP2020535138A (ja) | 2020-12-03 |
| MX2020003217A (es) | 2020-07-29 |
| CA3076496A1 (fr) | 2019-03-28 |
| EP3700550A4 (fr) | 2022-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50474A (fr) | Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1 | |
| MA55068A (fr) | Co-agonistes des récepteurs du glucagon et du glp-1 | |
| DK4058445T3 (da) | Glp-1-receptoragonist og anvendelse deraf | |
| DK3555064T3 (da) | GLP-1 receptoragonister og anvendelser deraf | |
| DK3806855T5 (da) | GLP-1-receptoragonister og anvendelser deraf | |
| DK3806955T3 (da) | GLP-1-receptoragonister og anvendelser deraf | |
| HUS2300006I1 (hu) | GIP és GLP-1 ko-agonista vegyületek | |
| MA54407A (fr) | Composés de co-agonistes du glucagon et du glp-1 | |
| EP3398961A4 (fr) | Triple activateur activant le récepteur du glucagon, du glp-1 et du gip | |
| DK3517538T3 (da) | Pyrazolopyridin-derivat med GLP-1-receptoragonistvirkning | |
| DK3350165T3 (da) | Farnesoid-X-receptoragonister og anvendelser deraf | |
| DK3551221T3 (da) | Hidtil ukendte t-cellereceptorer og immunterapi med anvendelse deraf | |
| IL262802A (en) | Glucagon-receptor selective polypeptides and methods of use thereof | |
| DK3609888T3 (da) | Farnesoid x-receptor-agonister og anvendelser deraf | |
| DK3322437T3 (da) | Glukagonderivat og en sammensætning omfattende et langtidsvirkende konjugat af samme | |
| EP3377521A4 (fr) | Co-agonistes à action longue durée des récepteurs du glucagon et du glp-1 | |
| HRP20181708T1 (hr) | Eksendin-4 derivati kao selektivni agonisti receptora glukagona | |
| EP3394091A4 (fr) | Co-agonistes des récepteurs de glucagon et de glp-1 | |
| DK3126381T4 (da) | Claudin-6-specifikke immunoreceptorer og t-celleepitoper | |
| DK3169703T3 (da) | Kimær antigenreceptor og anvendelse deraf | |
| DK3097313T3 (da) | Skrue, fastgørelsesanordning og anvendelse af en skrue | |
| DK3406264T3 (da) | Sammensætning omfattende GLP-1-receptoragonist og glucagonreceptoragonist og anvendelse deraf | |
| DK3277278T3 (da) | Kombinationsdoseringsform af en my-opioid receptorantagonist og et opioid | |
| MA52882A (fr) | Agonistes du récepteur glp-1 et leurs utilisations |